Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

Biotechnology patents: Court of Justice of the EU decides against patent theory of Monsanto: Monsanto v Cefetra & Ors (BLOG@IP::JUR) (EPLAW) (IPKat)

Prilosec / Losec (Omeprazole) – EU: General Court largely upholds European Commission decision in AstraZeneca v Commission (EPLAW) (IPKat)

An overview of the ‘Health Impact Fund’ model for accessible medicines (Spicy IP)

Pharma pay-and-procure symposium (IP finance)

Australia: The buck stops here for Dr Gray – FCA determines damages to Sirtex: University of Western Australia v Gray (IP Whiteboard)

EU: Review of Community plant varieties decisions: the ECJ speaks (JIPLP)

EU: Biotechnology patents: Court of Justice of the EU decides against patent theory of Monsanto: Monsanto v Cefetra & Ors (BLOG@IP::JUR) (EPLAW) (IPKat)

EU: DNA sequence patents and that JIPLP article: the sequel – Monsanto v Cefetra (JIPLP)

France: First Instance Court of Paris decision on file wrapper estoppel and on doctrine of equivalents: Institut Pasteur v. Siemens (EPLAW)

India: Novartis & Bayer appeals to be heard by the Supreme Court in the next 30 days (Spicy IP)

US: House passes patent settlement legislation as part of the War Funding Bill (FDA Law Blog)

US: Bilski v Kappos: What effects on biotechnology patents? (Patent Docs) (Holman’s Biotech IP Blog)

US: AMP v USPTO after Bilski v Kappos (Patent Docs)

US: NORD Chair/HP&M Director presents opening testimony at first ever FDA orphan drug hearing (FDA Law Blog)

US: Celsis files patent infringement complaint against CellzDirect and Invitrogen over pooled multi-cryopreserved hepatocyte products (Patent Docs)

Astelin (Azelastine) – US: Zydus admits infringing Meda’s Astelin patent, agrees not to market generic (Patent Docs)

Cozaar and Hyzaar – US: D C Circuit affirms District Court ruling concerning Losartan 180-day exclusivity forfeiture issue (FDA Law Blog)

Crestor (Rosuvastatin) – US: District Court Delaware finds AstraZeneca’s Crestor patent valid: AstraZeneca v Aurobindo (Patent Docs) (Docket Report)

Detrol (Tolterodine) – US: Pfizer files patent infringement suits against Mylan and Sandoz following Para IV challenges (Patent Docs)

Effexor (Venlafaxine) – US: Teva introduces first generic Effexor XR capsules in the United States; awarded 180-day period of marketing exclusivity (SmartBrief)

Effexor (Venlafaxine) – US: Wyeth files patent infringement complaints in SD New York and Delaware against Intellipharmaceutics following Para IV challenge (Patent Docs)

Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement complaint against Actavis following Para IV challenge (Patent Docs)

Lipitor (Atorvastatin) – US: District Court N D Illinois: Pay for delay settlement creates substantial controversy sufficient to support challenge to Lipitor patents: Pfizer v Apotex (Docket Report)

Prilosec / Losec (Omeprazole) – EU: General Court largely upholds European Commission decision in AstraZeneca v Commission (EPLAW) (IPKat)

Renvela (Sevelamer) – Impax Laboratories initiates challenge of Genzyme’s listed patent relating to Renvela; Genzyme files patent infringement complaints against Impax and Sandoz (SmartBrief) (Patent Docs)

Simcor (Niacin, Simvastatin) – US: Abbott Laboratories files patent infringement suit against Mylan following Para IV challenge (Patent Docs)

Zetia (Ezetimib) – US: Schering files patent infringement complaint against Mylan following Para IV challenge (Patent Docs)